company background image
VPRO logo

Viropro OTCPK:VPRO Stock Report

Last Price

US$0.000001

Market Cap

US$1.3k

7D

0%

1Y

0%

Updated

07 Jan, 2025

Data

Company Financials

VPRO Stock Overview

Through its subsidiaries, engages in the contract research, development, and manufacture of biotherapeutic proteins for the treatment of various diseases. More details

VPRO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Viropro Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Viropro
Historical stock prices
Current Share PriceUS$0.000001
52 Week HighUS$0.000001
52 Week LowUS$0.000001
Beta0
1 Month Change0%
3 Month Changen/a
1 Year Change0%
3 Year Change0%
5 Year Change-99.94%
Change since IPO-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

VPROUS BiotechsUS Market
7D0%1.9%0.7%
1Y0%-6.6%23.9%

Return vs Industry: VPRO exceeded the US Biotechs industry which returned -7.2% over the past year.

Return vs Market: VPRO underperformed the US Market which returned 24.4% over the past year.

Price Volatility

Is VPRO's price volatile compared to industry and market?
VPRO volatility
VPRO Average Weekly Movementn/a
Biotechs Industry Average Movement11.0%
Market Average Movement6.4%
10% most volatile stocks in US Market18.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: VPRO's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine VPRO's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/an/an/awww.viropro.net

Viropro Inc., through its subsidiaries, engages in the contract research, development, and manufacture of biotherapeutic proteins for the treatment of various diseases. The company is also involved in the transfer of its proprietary technologies for industrial production of biogeneric therapeutic proteins for the treatment of various diseases, such as cancer, diabetes, hepatitis, or multiple sclerosis. It manufactures biologics drugs, including bio-similars for pre-clinical, and Phase I, II, and III clinical trials; offers its clients with supply of mammalian cell proteins, such as monoclonal antibodies or recombinant proteins, or other cell-derived products; owns three clones that include two in insulin therapy and one for cancer therapy; and provides contractual research and manufacturing services to biotech and biopharmaceutical companies.

Viropro Inc. Fundamentals Summary

How do Viropro's earnings and revenue compare to its market cap?
VPRO fundamental statistics
Market capUS$1.27k
Earnings (TTM)US$0
Revenue (TTM)n/a

n/a

P/E Ratio

n/a

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VPRO income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$0
EarningsUS$0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did VPRO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/07 06:50
End of Day Share Price 2024/11/13 00:00
EarningsN/A
Annual EarningsN/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Viropro Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution